UPDATE: BMO Capital Markets Reiterates on Teva Pharmaceutical Industries Ltd. Following Announcement of CEO Resignation

By: Benzinga
In a report published Thursday, BMO Capital Markets analyst David Maris reiterated an Outperform rating on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ), but lowered the price target from $49.00 to $44.00. In the report, BMO Capital Markets noted, “In surprising news today, Teva announced the resignation of its president
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.